Clinical Trial

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-03; most recent amendment 2026-05-04.
Trial Details
NCT Number NCT07399977
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Venous Thromboembolism, Deep Venous Thrombosis
Enrollment 259 participants
Start Date 2026-01-30
Primary Completion 2030-01-30 (estimated)
Study Completion 2030-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-05